An observational study in Sleep Apnea, Obstructive, sponsored by National Taiwan University Hospital. Completed at 1 site in Taiwan. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-12-01.
Sponsored by National Taiwan University Hospital · Observational
Specific Aim
To verify the differentially expressed genes and pathways between normal and OSA patients, and OSA patients before and after CPAP treatment.
Genes with changes in expression of more than two-fold between normal and OSA patients as well as OSA patients before and after CPAP treatment were thought as confirmed and were selected for further validation study.
To correlate the confirmed genes with the clinical presentations and CPAP effects in another 50 OSAS subjects to validate the altered gene expressions and pathways involved.
To investigate the correlation of genes confirmed from RT-PCR (identified gene), another 50 OSAS subjects are included in the study. We analyze the correlation between identified gene and the clinical manifestations and CPAP effect in these 50 OSAS patients.
To investigate the functions of genes identified in the first and second year (gene of interest), we establish a cell model with human monocyte cell line U937. We investigate the function of gene of interest through overexpress or knockdown.
Objectives The objectives of this project are to confirm the gene profiled from comparing normal and OSA patients as well as OSA patients before and after CPAP treatment, to investigate the correlation between altered gene expression and clinical presentations and CPAP effects of the OSAS and to identify and confirm corresponding pathway. This study will enhance our understanding of the individual constitution on widely different clinical characteristics and therapeutic variations. All these efforts will also help us to interpret its molecular mechanisms and develop prediction and diagnosis strategies of OSAS. The long-term objectives are to develop therapeutic strategy other than CPAP of OSAS.
Obstructive sleep apnea syndrome (OSAS) is characterized with recurrent collapse of upper airway during sleep and resulted in hypoxia and sleep fragmentation, which resulted in cardiovascular diseases, metabolic disorders and neurocognitive dysfunctions. The cardiovascular complications attributed to OSAS included hypertension, coronary artery disease, heart failure and stroke. The mechanisms responsible for developments of cardiovascular sequelae included repeated episodes of hypoxia and hypercapnia, exaggerated negative intrathoracic pressure and bursts of sympathetic activity provoking surges in blood pressure and heart rate. Increase of inflammatory mediators, which included C-reactive protein, oxidative stress, adhesion molecules, vascular endothelial growth factor and proinflammatory cytokines, were thought to involve in the developments of cardiovascular diseases in patients with OSAS.
To clarify the exact mechanisms of OSAS and the linkage to cardiovascular complications, in our previous study, we used oligo microarray to genome-wide profile the gene expression patterns in OSAS patients and the changes of gene expressions before and after four-week CPAP treatment. The oligo-microarray data were processed with CRSD database and two-way hierarchical clustering method. The results showed the gene expression patterns were different between control subjects and OSA patients and CPAP treatment also altered the gene expression patterns. Totally 27 genes and four pathways were identified as target genes and pathways from comparing the gene pattern changes before and after CPAP treatment, which included apoptosis, oxidative phosphorylation, cell adhesion and activation and metabolism. To continue analyzing the gene pattern changes before and after CPAP treatment, we propose this three-year project to achieve the following goals: (1) To verify the differentially expressed genes and pathways between normal and OSA patients, and OSA patients before and after CPAP treatment. (2) To correlate the confirmed genes with the clinical presentations and CPAP effects in another 50 OSAS subjects to validate the altered gene expressions and pathways involved. (3) To establish a cell model to investigate the differentially expressed genes and the putative biological pathways involved in OSA syndrome. The information obtained by this approach is very useful to understand the pathogenic mechanism of OSA that leads to systemic complications and further therapeutic intervention may therefore be possible.
1,422 studies on the registry are indexed under Apnea; 159 are open to participants now.
This study's planned enrollment of 50 is below the median of 106 across 386 observational studies indexed under Apnea.
Browse Apnea studies →National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
Counted across the registry records on this site, refreshed daily.
From patients who were referred to sleep lab for suspect sleep apnea, we selected 50 male patients with age> 18 y/o. with severe OSAS, which were confirmed with by overnight PSG. All were free from neurologic events, chronic pulmonary disease, active infection and substance abuse. Female patients and patients under 18 y/o were excluded. All 50 subjects were treated with 4-week CPAP. All study subjects were admitted, on the day of baseline measurement and four weeks after CPAP use, for clinical evaluation, blood sampling and PSG. And all anti-hypertensive therapy was remained unchanged during the 4-week follow-up period. Changes of parameters, before and after CPAP treatment, were compared between two groups.
Exclusion Criteria:
CPAP treatment for 4 weeks
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital